Navigation Links
Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas
Date:11/4/2009

BOZEN, Italy, November 4 /PRNewswire/ -- Health Robotics today announced the worldwide presentation and launch of its new i.v.SOFT Workflow Engine at the American Society of Health-System Pharmacists' Mid-Year Meeting December 6-10 in Las Vegas. With the availability of the i.v.SOFT Workflow Engine, Health Robotics becomes the first and only company in the world to provide a total automation solution to fill the void of automated process control and patient safety in the I.V. Room.

i.v.SOFT's Workflow Engine represents a an additional revolutionary step by Health Robotics in completing its vision to fully automate IV Admixtures by providing state-of-the-art software automation tools to address the IV preparation of patient doses that cannot be physically handled by robotics technology due to a variety of reasons, such as hospital choices of ampoules, non-standard IV Bags, diverse Elastomeric infusion devices, etc.

The primary challenges in today's IV Admixture operations are serious medication errors such as drug exchange and accuracy mistakes, high costs, life-critical turn-around time, intravenous drugs waste, regulatory issues, and difficulty in maintaining adequately trained clinical staff. While market-leading robots CytoCare(TM) and i.v.STATION(TM) automatically and aseptically compound the majority of hazardous and non-hazardous IV doses, hospitals have demanded complementary automation solutions for the 20-30% of IV doses (depending on local market requirements) that need to be routed to manual compounding on BSCs (biological safety cabinets). i.v.SOFT Workflow Engine offers worldwide hospital pharmacies the ability to have their pharmacy technicians work more efficiently while at the same time reducing costs due to IV Admixtures that are typically lost or re-made.

"Building the i.v.SOFT Workflow Engine upon the product specifications, customer experience, software logic, and industrial component i
'/>"/>

SOURCE Health Robotics
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
3. Pragmedic Implements World-Class Healthcare Solution for Emaar Healthcare
4. PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009
5. Diabetics: 3tailer Partners with MyGlucoHealth on World's 1st Blood Glucose Meter with Wireless Bluetooth for Diabetes
6. Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs
7. Collaboration of Indianas Health Information Exchanges, State Organizations Submits Application for Health Information Technology Stimulus Funding
8. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
9. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
10. Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award
11. Frost & Sullivans 2009 Excellence in Healthcare Awards Banquet Honours Industrys Top Performers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... 2013 •    First of its kind research ... ,     New facility will help solve crop stresses ... Syngenta unveiled its new crop research facility during ... Innovation Center. The first of its kind, $72 million ... agricultural climate and precisely measure plant inputs – the ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... Calif., March 10 MannKind,Corporation (Nasdaq: MNKD ... recent market events:, MannKind is absolutely committed ... Technosphere(R) Insulin. We use our small,patient-friendly Medtone(R) inhaler ... a way that much more closely matches the ...
... Judith K. Gwathmey VMD, Ph.D., FACC,FAHA has served ... Inc. for twelve years. Gwathmey, Inc. is an ... evaluation,of lead compounds prior to their conversion into ... a campaign with other members of the,quiet rural ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... delay the growth of cancerous,tumors in patient-derived xenografts ... developed in ANAVEX labs using a sample,taken from ... cell sarcoma,is a rare type of melanoma (skin ...
Cached Biology Technology:MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 3Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 4Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 5Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 6
(Date:5/16/2013)... Fish fossils that are about 23 million years ... of the gobioid order, one of the most ... Researchers led by paleontologist Professor Bettina Reichenbacher from ... Department of Earth and Environmental Sciences at Ludwig-Maximilians-Universitaet ... comprehensive analysis of fish fossils which they assign ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
(Date:5/15/2013)... moderating gout risk, new research reveals that vitamin C, ... (urate) levels to a clinically significant degree in patients ... combination with allopurinol, appears to have a weak effect ... to the results published in the American College of ... , Gout is an inflammatory arthritis that causes excruciating ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Richard C. Willson has been named a 2010 Fellow ... (AAAS), which is the world,s largest general scientific society ... Willson is a professor of chemical and biomolecular engineering ... the AAAS for his "distinguished contributions to biomolecular recognition ...
... Conservation paleobiologists--scientists who use the fossil record to ... species to changes in their environment--are putting the ... the research in this emerging field provides examples ... environmental impacts, predict which species will be most ...
... Institute who have been studying prostate cancer cells for decades ... cancer progression. "This is the first demonstration of a ... a tumor to produce," said senior author Sal Pizzo, M.D., ... willing to bet there is also a connection in cancerous ...
Cached Biology News:University of Houston professor named 2010 AAAS Fellow 2Putting the dead to work 2Putting the dead to work 3Researchers learn why PSA levels reflect prostate cancer progression 2Researchers learn why PSA levels reflect prostate cancer progression 3
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Rabbit polyclonal to ADAMTS16 ( ... Antigen: Synthetic ... of human ADAMTS-16. Note: the amino ... Entrez GeneID: 170690 ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: